盐酸埃克替尼对中晚期表皮生长因子受体突变型非小细胞肺癌疗效及免疫指标的影响  

Therapeutic effect of icotinib hydrochloride on epidermal growth factor receptor mutant middle to advanced stage non-small cell lung cancer and its influence on immune markers

作　　者：赵秋红[1] 闫春良[1] 任冠军[1] ZHAO Qiuhong;YAN Chunliang;REN Guanjun(Department of Respiratory Medicine,Beijing Aerospace General Hospital,Beijing 100076,China)

机构地区：[1]北京航天总医院呼吸内科,北京1000760

出　　处：《癌症进展》2020年第15期1589-1592,共4页Oncology Progress

摘　　要：目的探讨盐酸埃克替尼对中晚期表皮生长因子受体(EGFR)突变型非小细胞肺癌疗效和免疫指标的影响。方法根据治疗方法的不同将130例中晚期EGFR突变型非小细胞肺癌患者分为观察组(采用盐酸埃克替尼治疗)和对照组(采用多西他赛注射液治疗),各65例。比较两组患者治疗1个月后的临床疗效、治疗期间的不良反应发生情况以及治疗后免疫指标的变化情况。结果治疗1个月后,观察组患者的总有效率为70.80%,疾病控制率为90.77%,分别高于对照组患者的53.85%和75.38%(P<0.05)。观察组中TNM分期为ⅢB、Ⅳ期患者的疾病控制率均高于对照组(P<0.05)。两组TNM分期为ⅢA期患者的总有效率和疾病控制率比较,差异均无统计学意义(P>0.05)。治疗后,观察组患者的CD3+、CD4+水平和CD4+/CD8+均明显高于对照组,CD8+水平明显低于对照组(P<0.01)。治疗期间,两组患者的不良反应以1~2级为主,皮疹的发生率最高。两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论盐酸埃克替尼治疗中晚期EGFR突变型非小细胞肺癌的临床疗效显著,可有效改善患者的免疫功能,且未增加不良反应。Objective To investigate the therapeutic effect of icotinib hydrochloride on patients with advanced epidermal growth factor receptor(EGFR) mutant non-small cell lung cancer(NSCLC) and its influence on immune markers.Method A total of 130 advanced patients with EGFR-mutant NS CL C were selected and divided into the observation group(icotinib hydrochloride) and control group(docetaxel injection) with 65 cases in either groups according to the treatment regimen.The clinical efficacy of the two groups of patients after 1 month of treatment was compared,the occurrence of adverse reactions during treatment was compared,and the alterations of immune markers after treatment were compared.Result The overall response rate was 70.80% and the disease control rate was 90.77% n the observation group,which were both higher than the 53.85% and 75.38% of the control group respectively(P<0.05).The disease control rate of the observation group in stage ⅢB and Ⅳ patients were significantly higher than those of the control group(P<0.05).There was no significant difference in terms of the response rate and disease control rate of stage ⅢA patients between the two groups(P>0.05).The levels of CD3^+,CD4^+ and CD4^+/CD8^+ were significantly higherin observation group after treatment than those in control group while the level of CD8^+ was significantly lower than that before treatment(P<0.01).The most common adverse events during the treatment were skin rash and the grades were majorly 1 to 2.Conclusion Icotinib hydrochloride has remarkable efficacy in the treatment of advanced EGFR mutant NS CL C,which could effectively improve the immune function of patients without raising the risk of adverse events.

关 键 词：表皮生长因子受体 突变 非小细胞肺癌 盐酸埃克替尼 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]